(CHRS) Coherus Oncology, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CHRS) Coherus Oncology, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Coherus Oncology, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to show how it competes in oncology markets; the page includes a real preview/sample of the analysis so you can evaluate style and content. Purchase the full version to receive the complete, ready-to-use report.
Product
LOQTORZI, PD-1 inhibitor
LOQTORZI is Coherus Oncology, Inc.’s lead branded oncology product and the core of its pivot into cancer care. It is a next-generation PD-1 inhibitor for solid tumors, including nasopharyngeal carcinoma, and is the only FDA-approved treatment in the U.S. for recurrent or metastatic NPC with gemcitabine and cisplatin. In 2024, Coherus Oncology, Inc. reported LOQTORZI net product revenue of about $7 million.
UDENYCA, pegfilgrastim biosimilar
UDENYCA, a pegfilgrastim biosimilar to Neulasta, is a long-acting G-CSF used as a 6 mg once-per-cycle dose to help neutrophil recovery after chemotherapy and cut febrile neutropenia risk. It gives Coherus Oncology, Inc. a steady supportive-care revenue base, with biosimilar pricing and hospital/clinic adoption driving access. In 2024, Coherus still cited UDENYCA as a core oncology franchise asset.
YUSIMRY, adalimumab biosimilar
YUSIMRY is Coherus Oncology, Inc.'s adalimumab biosimilar to Humira, used for rheumatoid arthritis, psoriasis, and Crohn’s disease. As a lower-cost biologic in the $20 billion-plus adalimumab market, it helps widen the Company beyond oncology into immune-mediated care. Its reach supports a broader prescriber base and diversifies revenue risk.
CIMERLI, ranibizumab biosimilar
CIMERLI, Coherus Oncology, Inc.’s ranibizumab biosimilar, targets the same VEGF-A pathway as Lucentis and is used for wet AMD, diabetic macular edema, and diabetic retinopathy. As a retina product, it gives Coherus a foothold in an ophthalmology market that treats millions of patients and relies on repeat intravitreal dosing.
- Product: Lucentis biosimilar
- Use: wet AMD, DME, DR
- Form: intravitreal injection
- Value: retina-market presence
Pipeline, 4 named immunotherapy programs
Coherus Oncology, Inc.’s 4-program pipeline is the main post-biosimilar growth engine: Casdozokitug, CHS-114, CHS-1000, and GSK4381562. These immunotherapy assets target immune checkpoints and the tumor microenvironment, aiming to expand beyond the company’s biosimilar base, which delivered $281.4 million in 2025 net product revenue.
- 4 named immunotherapy programs
- Checkpoint and TME targets
- Post-biosimilar growth driver
- 2025 net product revenue: $281.4M
Coherus Shifts Toward Oncology-Driven Revenue
Coherus Oncology, Inc.’s Product mix is led by LOQTORZI, its FDA-approved PD-1 therapy for recurrent or metastatic NPC, plus UDENYCA, YUSIMRY, and CIMERLI as revenue-supporting biosimilars. The shift is still early, but the mix is more oncology-focused than before. In 2025, net product revenue was $281.4 million.
| Product | Role | 2025 |
|---|---|---|
| LOQTORZI | Lead branded therapy | $7M 2024 |
| Biosimilars | Revenue base | $281.4M |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Coherus Oncology, Inc.’s product, pricing, place, and promotion strategy for clear market insight.
Editable Excel File
Turns Coherus Oncology’s 4Ps into a clear snapshot that quickly relieves analysis overload.
Reference Sources
Provides a concise, traceable bibliography linking each Coherus Oncology claim to primary industry reports, regulatory filings, and trusted datasets for faster, defensible decisions.
Place
U.S. headquarters, Redwood City, California
Coherus Oncology, Inc. is headquartered in Redwood City, California, and the U.S. is its core operating market. That Bay Area base supports corporate, regulatory, and commercial work close to major life-science talent and investors. Redwood City sits about 25 miles south of San Francisco, which helps speed hiring, partner access, and U.S. market execution.
Specialty oncology distribution
In 2024, LOQTORZI was distributed through oncology-focused channels, with access centered on cancer clinics and infusion sites, not mass retail. This buy-and-bill model fits specialist prescribing, where treatment starts in supervised settings and payer handling stays tied to oncology practices. The channel is built for physician demand, prior auth, and specialty support, which suits a niche, high-acuity cancer drug.
Specialty pharmacy and buy-and-bill
Coherus Oncology, Inc. sells its biosimilars through specialty pharmacy and buy-and-bill, the two main reimbursement paths for injectable biologics. This matters because payers and providers decide access and payment at the point of care, where medical-benefit claims are processed. In 2025, Coherus reported net product revenue of about $152 million, showing how channel mix directly supports sales execution.
Retina and rheumatology sites of care
CIMERLI and YUSIMRY are placed in specialist outpatient settings, so Coherus Oncology reaches patients where retina and rheumatology treatment decisions are made. Retina practices, rheumatology clinics, and related infusion sites are the key access points, and the company’s place strategy follows the treating physician.
This model fits high-touch biologic care, where the prescriber, site of care, and payer all shape access and uptake. For Coherus Oncology, that means the sales effort is built around specialty offices and infusion networks, not broad retail distribution.
- Specialist outpatient sites drive access.
- Retina and rheumatology are core channels.
- Infusion sites support treatment delivery.
- Place strategy follows the prescriber.
Partner-led reach, Junshi, Bioeq, Genentech, Surface, Vaccinex
Coherus Oncology, Inc. uses 5 named partners, Junshi, Bioeq, Genentech, Surface, and Vaccinex, to extend reach beyond its own sales force. These deals split work across development, manufacturing, and regional access, so Coherus can scale without building a full direct network in every market.
This model lowers fixed selling costs and shifts more execution risk to partners, which matters when oncology launches need speed and capital discipline. The mix also supports faster market entry in multiple geographies, instead of depending only on Coherus-owned distribution.
- 5 partner links expand reach
- Shared development cuts cost load
- Partner access speeds regional entry
- Less need for direct sales buildout
Specialty Channels Drive Coherus Oncology’s $152M 2025 Sales
Coherus Oncology, Inc. places its products through specialist oncology, retina, rheumatology, and infusion settings, not mass retail. This keeps access tied to prescribers, prior auth, and site-of-care decisions. In 2025, net product revenue was about $152 million, showing the channel mix was central to sales.
| Place factor | 2025 data |
|---|---|
| Core channels | Specialty pharmacy, buy-and-bill |
| Key sites | Oncology, retina, rheumatology |
| Net product revenue | About $152 million |
Preview the Actual Deliverable
Coherus Oncology, Inc. Reference Sources
The preview shown here is the actual Coherus Oncology 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready to use for strategy, pricing, product positioning, and promotional planning.
Promotion
Junshi co-commercialization for LOQTORZI
LOQTORZI is co-commercialized with Junshi Biosciences, giving Coherus Oncology, Inc. shared launch support and scientific messaging. The product won its first U.S. FDA approvals in 2023, including nasopharyngeal carcinoma and esophageal squamous cell carcinoma, which sharpened the launch story. The alliance also splits development and market-expansion work across 2 partners.
Oncology field force and medical affairs
Coherus Oncology, Inc. uses specialist sales teams and medical affairs to reach oncologists and other specialist prescribers, not mass consumers. This fits a market where treatment choices lean on trial data, guideline support, and payer access. The model is built for high-touch, evidence-led promotion across a narrow, high-value prescriber base.
Medical congress data
Coherus Oncology, Inc. uses medical congresses and scientific meetings to share clinical data on its oncology products and pipeline assets, which is key in a market where peer review drives trust. In 2025, major congresses like ASCO and ESMO drew tens of thousands of clinicians and researchers, giving the Company broad reach with physicians and payers. Strong congress readouts can support adoption, pricing, and future trial interest.
HCP education for biosimilars
Coherus Oncology, Inc. uses HCP education to cut adoption friction for UDENYCA, YUSIMRY, and CIMERLI by stressing biosimilarity, access, and reference-product comparability. The message fits three biosimilars across oncology, immunology, and ophthalmology, where physician and pharmacy buy-in drives uptake.
- Biosimilarity first
- Access and coverage matter
- Educates physicians and pharmacies
- Supports 3-product portfolio
Payer access and formulary messaging
Coherus Oncology, Inc. frames payer access and formulary messaging to hospitals, payers, and integrated delivery systems around clinical value and clean reimbursement fit. In specialty drugs, where access can decide uptake, this message helps reduce coverage friction and speed adoption.
- Targets payers and hospital systems
- Focuses on clinical value
- Supports formulary placement
- Fits specialty drug buying
Coherus Pushes LOQTORZI with Dual-Partner Promotion and ASCO/ESMO Reach
Coherus Oncology, Inc. promotes LOQTORZI through a co-commercialization model with Junshi Biosciences, which shares launch support and scientific messaging across 2 partners.
The Company leans on specialist sales, medical affairs, and congress data, with 2025 ASCO and ESMO drawing tens of thousands of clinicians and researchers.
Promotion is aimed at oncologists, payers, and hospitals, with HCP education focused on biosimilarity, access, and reimbursement fit.
| Channel | 2025 signal |
|---|---|
| Congresses | Tens of thousands attended |
| Co-promotion | 2 partners |
| Target | Specialists and payers |
Price
Specialty biologic pricing for LOQTORZI
LOQTORZI is priced like a branded specialty biologic, with IV use in oncology clinics and a narrow U.S. label in 2 approved indications, so Coherus Oncology can support higher revenue per treated patient.
Its pricing fits limited patient pools and specialist prescribing, where access, infusion, and payer controls matter more than broad retail demand.
That model helps Coherus Oncology defend gross value per dose, even if total volume stays small versus mass-market drugs.
Biosimilar discounting for UDENYCA
UDENYCA uses biosimilar discounting to win access, pricing below Neulasta to fit payer and protocol budgets. Neulasta’s pegfilgrastim market has long carried premium list pricing, so even a modest double-digit discount can shift formulary placement. That lower price is a core launch lever for Coherus Oncology, Inc., not a margin afterthought.
Biosimilar discounting for YUSIMRY
YUSIMRY, Coherus Oncology, Inc.’s adalimumab biosimilar, is priced to undercut Humira and drive switch demand in a market where Humira’s U.S. list price has been about $6,922 for a 2-pen pack. Coherus has used deep discounting to improve payer access and patient affordability, which matters in crowded inflammatory-disease therapy lines. Lower net price can speed formulary wins and adoption.
Biosimilar discounting for CIMERLI
CIMERLI uses biosimilar pricing against Lucentis, so Coherus Oncology, Inc. can lean on lower unit cost plus access terms when retina groups compare total treatment cost. In ophthalmology, buyers look at price, reimbursement, and buy-and-bill fit together, and that helps CIMERLI move into practice purchasing pathways.
- Cuts price vs Lucentis
- Supports payer access terms
- Fits retina buying decisions
- Helps pathway adoption
Reimbursement, rebates, and copay support
Pricing at Coherus Oncology, Inc. hinges on payer contracts, prior auth, and reimbursement economics, not list price. In specialty drugs, gross-to-net deductions can top 30%, so rebates and copay help can lift net access while keeping consumer retail pricing out of the model.
- Negotiate payer access first
- Use rebates to cut net price
- Support copays to aid uptake
Coherus Pricing: Premium Biologic Value, Biosimilar Discount Strategy
Coherus Oncology, Inc. prices LOQTORZI as a specialty biologic in 2 approved U.S. indications, so value per treated patient stays high even with low volume.
UDENYCA, YUSIMRY, and CIMERLI use biosimilar discounting to win payer access, with YUSIMRY set below Humira’s about $6,922 list price for a 2-pen pack.
Price here is mostly about formulary wins, prior auth, and net rebates, not retail demand.
| Product | Price role |
|---|---|
| LOQTORZI | Premium specialty pricing |
| YUSIMRY | Deep Humira discount |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.